Daria Gaut
Overview
Explore the profile of Daria Gaut including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, et al.
Leuk Lymphoma
. 2023 Oct;
65(1):69-77.
PMID: 37801340
The rate of MRD clearance in AML with standard consolidation chemotherapy is not well defined. A multi-institution retrospective analysis was performed on 107 consecutively treated AML patients in morphologic complete...
2.
Othman T, Quan M, Zhang S, Gaut D, Young P, Mahmood O, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Jun;
23(10):749-756.
PMID: 37336714
Background: The choice between nonmyeloablative chemotherapy (NMA-C) or autologous hematopoietic cell transplantation (autoHCT) as consolidation in primary central nervous system lymphoma (PCNSL), and timing of autoHCT differs among centers. We...
3.
Major A, Yu J, Shukla N, Che Y, Karrison T, Treitman R, et al.
Blood Adv
. 2023 Apr;
7(16):4528-4538.
PMID: 37026796
Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy...
4.
Gaut D, Oliai C, Mead M
Leuk Lymphoma
. 2023 Jan;
64(2):507-510.
PMID: 36647839
No abstract available.
5.
Othman T, Penaloza J, Zhang S, Daniel C, Gaut D, Oliai C, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Jul;
22(10):e947-e957.
PMID: 35858904
Background: Managing double-expressor lymphomas (DEL) is controversial given the dearth of data and lack of standardized guidelines on this high-risk subset of lymphomas. No prospective and few retrospective studies limited...
6.
Tabbara N, Sharp J, Gaut D, Pham T, Tang K, Oliai C, et al.
Am J Hematol
. 2022 Mar;
97(7):E249-E255.
PMID: 35358346
No abstract available.
7.
Kennedy V, Hui G, Azenkot T, Gaut D, Wieduwilt M, Oliai C, et al.
Am J Hematol
. 2022 Mar;
97(6):E191-E194.
PMID: 35266185
No abstract available.
8.
Mead M, Cederleuf H, Bjorklund M, Wang X, Relander T, Jerkeman M, et al.
Blood Adv
. 2021 Sep;
6(7):2120-2128.
PMID: 34570186
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive neoplasms with poor outcomes, commonly affecting older patients with comorbidities. This study aims to describe outcomes of older patients with...
9.
Tabbara N, Gaut D, Oliai C, Lewis T, de Vos S
Leuk Res Rep
. 2021 Aug;
16:100260.
PMID: 34354920
Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19. The L-MIND (NCT02399085) trial, an open-label, single-arm, phase II study of Tafasitamab (TAFA) plus lenalidomide (LEN), reported progression-free survival...
10.
Gaut D, Mead M
Leuk Lymphoma
. 2020 Nov;
62(1):8-31.
PMID: 33138674
Allogeneic hematopoietic stem cell transplantation (alloHCT) results in improved outcomes for acute myeloid leukemia (AML) patients compared to consolidation chemotherapy in transplant-eligible patients with adverse-risk disease. Despite achieving a complete...